Valerian
Best-in-class: Valerian Root
A traditional sleep-and-calm botanical that gently supports GABA activity to ease the transition into sleep.
Valerian quick facts
| Suggested dose | As directed, ~30–60 min before bed. |
| How often | nightly |
| Who it's for | Gentle, non-hormonal sleep and relaxation support. |
Meta-analyses support subjective sleep quality, though the objective polysomnography data is weaker than the questionnaires. The effect builds over two to four weeks rather than working on night one, which is why people take a single dose, feel nothing and abandon it. The smell is genuinely unpleasant and is the main adherence obstacle. Pairs conventionally with hops, and that combination has better data than valerian alone.
How Valerian actually works
Valerenic acid modulates GABA-A receptors and inhibits the enzyme that breaks GABA down, so more GABA persists at the synapse. The valepotriates were once thought to be the actives but are unstable and probably not responsible. The mechanism remains less precisely characterized than the popularity suggests.
Where to get Valerian
Buy Valerian Root at Thorne →The evidence for Valerian
Graded by what exists behind each claim.
✅ Clinically validated
- Meta-analyses suggest modest improvement in subjective sleep quality, with mixed objective results.
- Used traditionally for mild anxiety and restlessness.
📊 Correlative data
- Long history of use for sleep aligns with the (modest) trial signal.
🧪 Theoretical / extrapolated benefits
- GABA-ergic mechanism is proposed but not fully characterized.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Valerian actually does
Valerian root is a mixture — valepotriates, volatile oils, lignans, free amino acids — and for most of the last century nobody could say which part did anything. That changed with a sesquiterpenoid: valerenic acid.
The receptor work is unusually clean for a botanical. Valerenic acid and valerenol bind a specific site on GABA-A receptors with nanomolar affinity — a site distinct from the benzodiazepine site — and both enhance the response to GABA at multiple recombinant GABA-A subtypes. A single point mutation, N265M, in the beta-2 or beta-3 subunit strongly reduced the drug response. In living mice both compounds were anxiolytic in the elevated plus maze and the light/dark choice test, and in beta-3 N265M point-mutated mice the anxiolytic action of valerenic acid was absent Benke 2009. That is a genetic demonstration, not a correlation: neurons expressing beta-3-containing GABA-A receptors are the cellular substrate.
Why that residue matters more than the paper says. Asparagine 265 on the beta subunit is the transmembrane residue that carries the action of the intravenous anesthetic etomidate and of loreclezole. Valerenic acid is therefore not vaguely GABAergic; it is acting at a defined transmembrane pocket that general anesthetics use. That is a mechanistic reason to take the pre-surgical warning seriously rather than a precaution copied off a list.
The extract behaves as its valerenic acid content predicts. The anxiolytic activity of a valerian extract tracked with valerenic acid rather than with total extract weight Becker 2014, which is what turns standardization from a marketing word into a dosing instrument.
What is not the mechanism. Valerian root contains free GABA, and the idea that this explains the effect is still repeated. It does not: oral GABA does not usefully cross the blood-brain barrier Boonstra 2015, and the amount in a capsule of root is trivial besides.
Cell, rodent, human — and where it stops
Receptor to rodent: nanomolar affinity, beta-3-dependent anxiolysis, abolished by a point mutation Benke 2009, with the extract's effect tracking its valerenic acid content Becker 2014. This is a stronger preclinical chain than most botanicals have.
Human, the meta-analysis everyone quotes. Sixteen eligible randomized placebo-controlled trials totaling 1,093 patients. Six of them reported a dichotomous sleep-quality outcome and the pooled relative risk of improved sleep was 1.8 (95% CI 1.2–2.9). The same review states that most studies had significant methodological problems, that doses, preparations and treatment lengths varied considerably, and that there was evidence of publication bias in that summary measure Bent 2006. Publication bias means 1.8 is an upper bound.
Human, the trial that put people in a sleep laboratory. Sixteen older women with insomnia, mean age 69.4 plus or minus 8.1 years, took 300 mg of concentrated valerian extract or placebo 30 minutes before bed for 2 weeks in a randomized double-blind crossover, with polysomnography on nine laboratory nights plus home actigraphy and daily sleep logs. There were no statistically significant differences from placebo after a single dose or after two weeks on any measure of sleep latency, wake after sleep onset, sleep efficiency or self-rated quality. Against its own baseline, wake after sleep onset increased by 17.7 plus or minus 25.6 minutes on valerian, p = 0.02, and did not increase significantly on placebo Taibi 2009.
Human, the combinations. A valerian-hops combination was tested against diphenhydramine and placebo in insomnia Morin 2005, a fixed valerian-hops extract was tested in primary insomnia Salter 2010, and Ze 91019 was tested in a randomized double-blind prospective study Koetter 2007. Hops has its own GABAergic pharmacology; a combination result does not belong to valerian.
The obstacle is a mismatch between what was measured and what was found. The positive signal is subjective and pooled across trials the reviewers themselves called methodologically poor Bent 2006. The trial that measured sleep objectively, in the group with the most room to improve, found nothing — and found the one objective change in the wrong direction Taibi 2009. The reader buying this is typically an adult under 50 with sleep-onset difficulty and no diagnosis, and that population has never been studied with polysomnography at all.
Valerian — which form, and does it matter
Standardization is the entire purchase, and it is one number. Valerenic acid is the constituent with the receptor Benke 2009 Becker 2014. European drug-grade valerian is specified on valerenic acid content; food-supplement valerian frequently is not. A label reading “valerian root 500 mg” tells you the weight of powder and nothing about the only molecule with a measured target. A label reading “valerian root extract 300 mg, standardized to 0.8% valerenic acids” tells you the capsule carries 2.4 mg of it, which is a dose you can compare between products and across time.
Extraction chemistry splits the shelf in two. Valerenic acid is a lipophilic sesquiterpenoid and water extracts it poorly, so a valerian tea and an ethanolic dry extract are not weaker and stronger versions of one product — they are different preparations with different constituent profiles. Valepotriates, the other historically credited group, are unstable and degrade on storage, which is a second reason two bottles of the same herb are not the same drug.
Match a trial if you want a trial's result. The polysomnography trial used 300 mg of a concentrated extract 30 minutes before bed Taibi 2009; the meta-analysis pools preparations and doses that varied considerably Bent 2006. The card's “as directed, about 30–60 minutes before bed” specifies a timing and no dose, which is the norm for this herb and is the reason its literature is so hard to add up.
A valerian-hops product is a different purchase. It has its own trials Morin 2005 Salter 2010 Koetter 2007 and it does not inherit valerian's, and it cannot be dose-compared to a single-herb capsule on either constituent.
What would have to be true, and how you would know it was not
1. Sleep quality and sleep latency, separated, on a diary with a real baseline. Fourteen nights of diary before the first capsule, then 28 nights on a valerenic-acid-standardized extract 30 minutes before bed. Score the Pittsburgh Sleep Quality Index at day 0 and day 28 as the formal instrument. Predict a small improvement in subjective quality and none in latency, because that is precisely the shape of the literature: a pooled relative risk of 1.8 on subjective sleep quality Bent 2006 against nothing on any objective measure Taibi 2009.
2. The prediction that cuts against the product, and it is a specific number in a specific direction. Predict that wake after sleep onset gets slightly worse at two weeks. In the only polysomnography trial, two weeks of nightly valerian increased wake after sleep onset by 17.7 minutes against its own baseline, p = 0.02 Taibi 2009. Most people never measure this, because they only count how long it took to fall asleep. Count the minutes awake in the night as a separate line in the diary and be willing to see them go up.
3. If you use an actigraph or a validated consumer tracker, predict that it disagrees with your diary. Both were measured in the same women and both were flat while a subjective literature says otherwise Taibi 2009 Bent 2006. When they disagree, the tracker is the less flattering and the more informative of the two.
What will fool you: the smell. Valerian is unmistakable and self-blinding is impossible, so expectation rides along with every dose — and a minority experience frank stimulation, which means a bad night on valerian is data rather than noise.
What nobody has tested yet
Nobody has run a dose-response trial on valerenic acid content. The receptor work names the molecule and the mutant-mouse work proves the site Benke 2009, and no human trial has ever randomized people to two extracts differing only in valerenic acid percentage. That single study is what the whole standardization argument requires and it does not exist.
Nobody has genotyped a valerian trial at GABRB3. The anxiolytic effect is beta-3-dependent in mice Benke 2009; common human variation in the beta-3 subunit has never been used to stratify responders, which is the obvious explanation for why this herb works dramatically for some people and not at all for others.
Nobody has tested it in the people who buy it. The polysomnography trial was 16 women averaging 69 years old Taibi 2009. Adults aged 25 to 50 with sleep-onset insomnia and no diagnosis have never been studied objectively.
And nobody has characterized the paradoxical response. Stimulation instead of sedation is reported often enough to be real and has never been quantified, phenotyped or explained — which is remarkable for a herb with 16 randomized trials behind it Bent 2006.
Valerian — its own safety story, not its category's
Idiosyncratic liver injury is the risk specific to this root. There are published cases of valerian-associated hepatotoxicity Cohen 2008 Vassiliadis 2009. The honest framing has two halves. It is not dose-dependent, not predictable and not preceded by a warning symptom, so no dose is “safe” in the way a threshold implies. And attribution in herbal liver injury is genuinely hard — multi-ingredient products, no retained samples, no product testing — so a handful of case reports against an enormous exposure base is a low rate, and saying so is more useful than either hiding it or inflating it. The practical rule: if unexplained fatigue, nausea, right upper quadrant discomfort, dark urine or yellowing of the eyes appears, stop and get ALT, AST and bilirubin.
Paradoxical stimulation in a minority is the effect nobody warns about. If you are lying there more awake than usual, that is a real response and the answer is to stop, not to take more.
Anesthesia, with a mechanism. Stop it two weeks before surgery. The reason is not generic herbal caution: valerenic acid acts at the beta-subunit transmembrane site around asparagine 265 Benke 2009, which is the site etomidate uses, and additive action at an anesthetic site is worth an anesthetist knowing about. Withdrawal-like symptoms have been reported after abrupt discontinuation of long-term high-dose use, so taper rather than stopping dead.
Additive sedation with alcohol, benzodiazepines, z-drugs, opioids and sedating antihistamines. The combination impairs driving more than either component alone and more than most people expect, and it is the more likely harm on any given night than the liver.
Who should not take it: anyone with liver disease or a raised ALT; anyone on a sedative or drinking that evening; anyone within two weeks of a scheduled anesthetic; and anyone using it nightly for chronic insomnia instead of cognitive behavioral therapy for insomnia, which is the first-line treatment and which outperforms a relative risk of 1.8 on a subjective scale Bent 2006 Taibi 2009.
Sources read for this page
- Benke D, Barberis A, et al. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology 2009 · PMID 18602406
- Becker A, Felgentreff F, et al. The anxiolytic effects of a Valerian extract is based on valerenic acid. BMC Complementary and Alternative Medicine 2014 · PMID 25066015
- Bent S, Padula A, et al. Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine 2006 · PMID 17145239
- Taibi DM, Vitiello MV, et al. A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Medicine 2009 · PMID 18482867
- Morin CM, et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial.. Sleep 2005 · PMID 16335333
- Salter S, et al. Treating primary insomnia - the efficacy of valerian and hops.. Australian Family Physician 2010 · PMID 20628685
- Koetter U, et al. A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder.. Phytotherapy Research 2007 · PMID 17486686
- Cohen DL, Del Toro Y. A case of valerian-associated hepatotoxicity. Journal of Clinical Gastroenterology 2008 · PMID 18431248
- Vassiliadis T, Anagnostis P, et al. Valeriana hepatotoxicity. Sleep Medicine 2009 · PMID 19138557
- Boonstra E, de Kleijn R, et al. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Frontiers in Psychology 2015 · PMID 26500584
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: How long you lie there before you go under — estimated afterwards, not watched on a clock, because a clock you keep checking becomes its own insomnia. Valerian's GABAergic action is an onset mechanism, so 3 a.m. waking and early-morning waking sit outside what it claims and will not answer to it.
- How long before it means anything: Two weeks of consecutive nights. Its record is modest and subjective quality improves in trials before anything objective does, so an effect large enough to spot on a single night is more likely to be the night than the root.
- What will fool you: The smell, which is unmistakable and makes self-blinding impossible, so your expectation rides along with every dose. There is also a minority in whom it does the opposite and stimulates — if you are lying there more awake than usual, that is a real paradoxical response and not a signal to take more.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Valerian — safety & side effects
- Morning grogginess, vivid dreams and — paradoxically, in a minority — stimulation and insomnia, which is the effect nobody warns about.
- Rare idiosyncratic liver injury has been reported. It is not dose-dependent and not predictable, so the practical rule is to stop and get liver enzymes checked if you develop unexplained fatigue, nausea, dark urine or yellowing of the eyes. Reports for valerian exist and are rare.
- Withdrawal-like symptoms have been reported after abrupt discontinuation of long-term high-dose use. Stop two weeks before surgery (interacts with anesthesia).
The same on every page it applies to. Read it here; it is not repeated research.
- Additive sedation with alcohol, benzodiazepines, z-drugs, opioids and antihistamines. The combination impairs driving more than either alone and more than most people expect.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Valerian in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Valerian
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | Liver enzymes — isolated hepatotoxicity reports, mostly in combination products |
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease is a common hidden cause of the insomnia this treats |
| Ferritin | Low iron is a common and cheap-to-fix cause of poor sleep and restless legs |
The Sleep Quality & Recovery panel covers these in one order — 11 markers, $172.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Valerian — frequently asked questions
What is Valerian?
A traditional sleep-and-calm botanical that gently supports GABA activity to ease the transition into sleep.
What is the suggested dose of Valerian?
As directed, ~30–60 min before bed. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Valerian dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Valerian?
Coach Cam sources Valerian from Thorne, with 10% off auto-applied at checkout — use the buy link on this page.
Valerian inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Valerian is used for
Valerian appears under 2 goals in the goal router.
Related Sleep supplements
Where this goes next
Valerian is the onset arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.